Context Therapeutics (CNTX) announced Karen Smith as interim chief medical officer. Smith replaces Claudio Dansky Ullmann, who will be leaving the company effective May 10. Smith will continue in a dual capacity as interim CMO and a member of the company’s board of directors while the company conducts a search for a new, full-time CMO. Smith will take over key responsibilities on an interim basis, ensuring continuity in strategic guidance for the company’s clinical development programs. Smith has served on Context’s board since 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
- Context Therapeutics presents preclinical data on CT-95
- Context Therapeutics initiated with an Outperform at William Blair
- Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion
- Context Therapeutics Begins Phase 1 Trial for CT-95